Save the Date!

Cholangiocarcinoma Foundation Annual Conference
February 3-5, 2016
Salt Lake City, Utah



In cooperation with:

This event brought together subject matter experts in the field of cholangiocarcinoma including clinical physicians, researchers, palliative care nurses, pharmaceutical and government representatives, and patient advocates.

Key opinion leaders and other professionals in the medical and scientific communities came together to collaborate and exchange knowledge. Throughout the program, attendees were provided opportunities to promote dialogue, foster innovation, and share expertise with colleagues worldwide.

This annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by:

  • Presenting current data on translational and basic research activities
  • Increasing the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma
  • Stimulating cross-cooperation and sharing best practices by developing, strengthening, and supporting collaborations through working groups


Participants

Oral Abstract Presentations

Sessions

Poster Presentations

Countries Represented

Canada
Israel
Thailand
United Kingdom
United Statesflags


Presenters
Mitesh Borad, Mayo Clinic,
Eric Collison
, University of California San Francisco and
Andrew X. Zhu
, Dana Farber/Harvard Cancer Center

Increasing Clinical Trials in Cholangiocarcinoma

John Bridgewater, University College, London
Clinical Trials in Cholangiocarcinoma: ABC Experience

Michele Carbone, University of Hawaii
BAP1 Mutations-Spectrum and Biology in Cancer

James Ferrell, The Arbinger Institute
Keynote Speaker

Randi Isaacs, Novartis Institute Biomedical Research
FGFR Alterations in Cancer

Keith Lindor, Arizona State University
NASH and PSC

Funda Meric-Bernstam, MD Anderson Cancer Center

Tumor Profiling and Investigational Therapeutics

Ben Stanger, University of Pennsylvania
Liver Development and Plasticity

Laura Wood, Johns Hopkins University School of Medicine
Somatic Mutation Profiling in Cholangiocarcinoma

Kate Yen, Agios Pharmaceutical
IDH1 Mutation in Cholangiocarcinoma

Lei Zheng
, Johns Hopkins University School of Medicine
Potential of Immunotherapy for Solid Tumors including Cancers of the Bile Duct

Oral Abstract Presentations

Dr. Renuka Iyer, Roswell Park Cancer Institute
Gemcitabine, Capecitabine & Bevacizumab in Patients with Advanced BC- Final Results of a Multicenter Phase II Study

Dr. Supriya Saha, Massachusetts General Hospital Cancer Center
Using Model Systems to Understand IDH Mutant Cholangiocarcinoma

Rachna Shroff, The University of Texas MD Anderson Cancer Center
Retrospective Review of Treatment Given to Unresectable Cholangiocarcinoma Patients: What is the Role of Chemoradiation?

Dr. Daniela Sia, Icahn School of Medicine at Mount Sinai
Massive Parallel Sequencing Uncovers Actionable FGFR2-PPHLN1 Fusion and ARAF Mutations in Intrahepatic Cholangiocarcinoma

Huiping Zhou, Virginia Commonwealth University
Conjugated Bile Acids Promote Cholangiocarcinoma Cell Invasive Growth via Activation of Sphingosine 1-phosphate Receptor 2


Poster Presentations

Roongruedee Chaiteerakij, Mayo Clinic
Difference in pattern of somatic mutations between PSC-related CCA and non-PSC related CCA

Jack Chen and Jiarui Li, Simon Fraser University
Mutational Landscape of Intrahepatic Cholangiocarcinoma

Nasra Giama, Mayo Clinic
The International Hepatobiliary Neoplasia Registry and Biorepository

Talia Golan, Sheba Medical Clinic, Israel
Biliary and Pancreatic Malignancies in Jewish BRCA1 and BRCA2 Mutation Carriers

Lipika Goyal, MGH Cancer Center
A Phase II trial of Cabozantinib (XL-184) in Patients with Advanced Cholangiocarcinoma (CCA)

Isabella Guajardo, UCSF
Cholangiocarcinoma and the Internet: What Doctors Need to Know to Best Help Your Patients

Margaret Hill, University of Rochester
Mcl-1 Regulates Autophagy in Intrahepatic Cholangiocarcinoma

Muthusamy Kunnimalaiyaan, Medical College of Wisconsin
Targeted Inhibition of the Akt Pathway in Cholangiocarcinoma by MK2206

Yong Sun Lee, University of Texas Medical Branch
nc886, a Cellular Non-Coding RNA that Plays a Tumor Surveillance Role in the Protein Kinase R Pathway in Cholangiocarcinoma

Maria Lozada, Medical Clinic
A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma

Lauren Rosati, Johns Hopkins University
Adjuvant Chemoradiation Therapy in Cholangiocarcinoma: A Single-Institution Experience

Hassan Shaleh, Mayo Clinic
Antitumor Effect of the Potent FGFR Inhibitor Ponatinib on an FGFR2-Fusion Driven Cholangiocarcinoma Mouse Model

Rachna Shroff, The University of Texas MD Anderson Cancer Center
Orthotopic liver transplant (OLT) in the Treatment of Hilar and Intrahepatic Cholangiocarcinomas: Preliminary Experience

Yaman Suleiman, H. Lee Moffitt Cancer Center and Research Institute
The Influence and Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) and PD-L1 Overexpression in Cholangiocarcinoma

Suebpong Tanasanvimon, Chulalongkorn University, Thailand
A Comparison of miRNA Expression Patterns between OV-CCA and non-OV CCA

Mingxin Zuo, UT MD Anderson Cancer Center
Novel Therapeutic Strategy Targeting Hedgehog Signaling & mTOR Pathways in Biliary Cancer

Agios Pharmaceutical

AMMF – The Cholangiocarcinoma Charity, United Kingdom

Arizona State University

Bili Project Foundation

Brigham and Women’s Hospital/Harvard Medical School

Chulalongkorn University, Thailand

Columbia University

Foundation Medicine

H. Lee Moffitt Cancer Center and Research Institute

Huntsman Cancer Institute

Icahn School of Medicine at Mount Sinai

Johns Hopkins University School of Medicine

Massachusetts General Hospital Cancer Center

Mayo Clinic

Medical College of Wisconsin

Memorial Sloan Kettering Cancer Center

Novartis Institutes for Biomedical Research

Oregon Health and Science University

Pinnacle Biologics, Inc.

Roswell Park Cancer Institute

Rutgers University

Sheba Medical Center, Israel

Simon Fraser University, Canada

Target Cancer Foundation

Texas A&M HSC

Tom Baker Cancer Centre, Canada

UCL Cancer Institute

Unity Point Healthcare

University of California San Francisco

University of Chicago

University of Hawaii Cancer Center

University of Manchester/The Christie NHS Foundation Trust, United Kingdom

University of Pennsylvania

University of Rochester

University of Southern California

University of Texas Medical Branch

University of Utah

University of Virginia

USC Norris Comprehensive Cancer Center

UT MD Anderson Cancer Center

Utah Cancer Specialists

Vanderbilt-Ingram Cancer Center

Virginia Commonwealth University

Virginia Mason Medical Center

Weill Cornell Medical College


Who Should Attend?

  • Researchers
  • Clinical physicians
  • Oncologists
  • Radiologists
  • Surgeons
  • Gastroenterologists
  • Hematologists
  • Nurses specializing in oncology, intensive care, and palliative care
  • Pharmaceutical Companies
  • Government Regulators